Free health fair connects Ottawa seniors and caregivers with local supports - CTV News

When Tracy Slaney imagined her life after retirement, she says she pictured travelling the world with her husband. But like many caregivers in Canada, the cost of looking after her loved ones means she had to put her plans on hold. “Those retirement plans that I once had are gone. They are decimated,” she said. In 2014, she became a caregiver for her father after he was diagnosed with terminal cancer. Within days of his passing, her mother received a dementia diagnosis. Slaney then stepped into a caregiver role for her until she died in 2019. On Valentine’s Day 2020, she found her husband had been diagnosed with stage four colorectal cancer. She spent most of her time, energy and finances caring for him, until he passed away in April this year. “I’ve been caregiving for 12 years, back-to-back,” she said. Story continues below advertisement

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.